Bug fix again

RAPath Bot · RAPath Bot · commit 70bd665e58a6 · 2026-07-12T08:59:00.000+10:00
diff --git a/sites/eu/docs/guidance-documents/guidance-by-device-class.md b/sites/eu/docs/guidance-documents/guidance-by-device-class.md
@@ -91,6 +91,6 @@ MDCG 2020-10 is listed twice in the guidance index with conflicting subjects. Ve
 
 - [MDCG guidance by topic](./mdcg-guidance.md)
 - [MEDDEV guidance index](./meddev-guidance-index.md)
-- [Forms & application links](./forms-application-links)
+- Forms & application links
 
 MDCG 2020-10 is listed in the guidance index as addressing 'Electromagnetic compatibility and safety' for active devices. Verify this is the correct and sole classification for this document across all site pages.
diff --git a/sites/eu/docs/guidance-documents/mdcg-guidance.md b/sites/eu/docs/guidance-documents/mdcg-guidance.md
@@ -121,6 +121,6 @@ Guidance is organised by topic on the Commission website. New and revised docume
 
 - [Guidance by device class](./guidance-by-device-class.md)
 - [MEDDEV guidance index](./meddev-guidance-index.md)
-- [NB-MED recommendations](./nb-med-recommendations)
-- [EC blue guide — market surveillance](./ec-blue-guide)
+- NB-MED recommendations
+- EC blue guide — market surveillance
 - [Legislation — MDR key articles](/legislation/mdr-key-articles)
diff --git a/sites/eu/docs/notified-bodies/what-notified-bodies-do.md b/sites/eu/docs/notified-bodies/what-notified-bodies-do.md
@@ -81,10 +81,10 @@ All EU notified bodies must be in NANDO to be legally authorised to issue MDR/IV
 ## Related pages
 
 - [How to choose a notified body](./how-to-choose-nb.md)
-- [NANDO database](./nando-database)
-- [Audit process & timelines](./audit-process-timelines)
-- [Unannounced audits](./unannounced-audits)
-- [Scrutiny procedure (Art. 54)](./scrutiny-procedure)
+- NANDO database
+- Audit process & timelines
+- Unannounced audits
+- Scrutiny procedure (Art. 54)
 - [Conformity assessment overview](/pre-market/conformity-assessment/conformity-assessment-overview)
 
 ---
diff --git a/sites/eu/docs/post-market/adverse-event-reporting/what-must-be-reported.md b/sites/eu/docs/post-market/adverse-event-reporting/what-must-be-reported.md
@@ -108,7 +108,7 @@ Full information is submitted in the **final report** after investigation is com
 - [Reporting timeframes](./reporting-timeframes.md)
 - [How to report — NCAs](./how-to-report-ncas.md)
 - [EUDAMED vigilance module](./eudamed-vigilance-module.md)
-- [Trend reporting](./trend-reporting)
+- Trend reporting
 - [When an FSCA is required](/post-market/field-safety-corrective-actions/when-fsca-required)
 
 ---
diff --git a/sites/eu/docs/post-market/eudamed-registration/overview.md b/sites/eu/docs/post-market/eudamed-registration/overview.md
@@ -105,8 +105,8 @@ Always verify current status at **ec.europa.eu/tools/eudamed** — the Commissio
 
 - [Economic operator registration](./economic-operator-registration.md)
 - [Device registration & UDI upload](./device-registration-udi.md)
-- [Certificates & notified body data](./certificates-nb-data)
-- [Public-facing modules & timelines](./public-modules-timelines)
+- Certificates & notified body data
+- Public-facing modules & timelines
 - [EUDAMED UDI registration](/pre-market/udi-system/eudamed-udi-registration)
 - [EUDAMED vigilance module](/post-market/adverse-event-reporting/eudamed-vigilance-module)
 
diff --git a/sites/eu/docs/post-market/labelling-advertising/labelling-requirements.md b/sites/eu/docs/post-market/labelling-advertising/labelling-requirements.md
@@ -109,7 +109,7 @@ NCAs enforce labelling requirements during market surveillance inspections. Non-
 - [GSPR Chapter III — IFU & labelling](/pre-market/gspr/chapter-iii-ifu-labelling)
 - [UDI labelling requirements](/pre-market/udi-system/udi-labelling-requirements)
 - [Advertising rules](./advertising-rules.md)
-- [Permitted & prohibited claims](./permitted-prohibited-claims)
+- Permitted & prohibited claims
 
 ---
 
diff --git a/sites/eu/docs/post-market/post-market-surveillance/annual-reports-psur.md b/sites/eu/docs/post-market/post-market-surveillance/annual-reports-psur.md
@@ -133,7 +133,7 @@ The PSUR cannot be completed without the **PMCF evaluation report** (MDR) or **P
 - [PMS requirements by class](./pms-requirements.md)
 - [Distribution records](./distribution-records.md)
 - [Post-market data in technical documentation](/pre-market/technical-documentation/post-market-data-in-tech-doc)
-- [PMCF plan and evaluation report](./pmcf)
+- PMCF plan and evaluation report
 
 ---
 
diff --git a/sites/eu/docs/post-market/post-market-surveillance/pms-requirements.md b/sites/eu/docs/post-market/post-market-surveillance/pms-requirements.md
@@ -175,7 +175,7 @@ This creates the lifecycle loop that is central to MDR/IVDR's approach — the t
 - [PMS plan and PMS report — Annex III](/pre-market/technical-documentation/post-market-data-in-tech-doc)
 - [Annual reports / PSUR](./annual-reports-psur.md)
 - [Distribution records](./distribution-records.md)
-- [PMCF plan and evaluation report](./pmcf)
+- PMCF plan and evaluation report
 - [Post-market overview](/post-market/post-market-overview)
 
 ---
diff --git a/sites/eu/docs/pre-market/conformity-assessment/annex-ix-qms-tech-doc.md b/sites/eu/docs/pre-market/conformity-assessment/annex-ix-qms-tech-doc.md
@@ -132,7 +132,7 @@ Given current notified body capacity constraints, manufacturers should initiate
 
 - [Conformity assessment — overview](./conformity-assessment-overview.md)
 - [Annex X — EU type examination](./annex-x-type-examination.md)
-- [Annex XI — Product verification](./annex-xi-product-verification)
+- Annex XI — Product verification
 - [EU Declaration of Conformity](./eu-declaration-of-conformity.md)
 - [Notified bodies](/notified-bodies/what-notified-bodies-do)
 - [Scrutiny procedure (Art. 54)](/notified-bodies/what-notified-bodies-do)
diff --git a/sites/eu/docs/pre-market/conformity-assessment/annex-x-type-examination.md b/sites/eu/docs/pre-market/conformity-assessment/annex-x-type-examination.md
@@ -132,7 +132,7 @@ This route provides stronger product-level assurance but is resource-intensive.
 - [Conformity assessment — overview](./conformity-assessment-overview.md)
 - [Annex IX — QMS + Tech Doc](./annex-ix-qms-tech-doc.md)
 - [EU Declaration of Conformity](./eu-declaration-of-conformity.md)
-- [CE marking requirements](./ce-marking-requirements)
+- CE marking requirements
 - [Notified bodies](/notified-bodies/what-notified-bodies-do)
 
 ---
diff --git a/sites/eu/docs/pre-market/conformity-assessment/class-i-self-declaration.md b/sites/eu/docs/pre-market/conformity-assessment/class-i-self-declaration.md
@@ -125,7 +125,7 @@ Competent authorities **can and do** inspect Class I manufacturers. Non-complian
 
 - [Conformity assessment — overview](./conformity-assessment-overview.md)
 - [EU Declaration of Conformity](./eu-declaration-of-conformity.md)
-- [CE marking requirements](./ce-marking-requirements)
+- CE marking requirements
 - [Class I · IIa · IIb · III](/pre-market/classification/mdr-classes)
 - [EUDAMED registration](/post-market/eudamed-registration/overview)
 
diff --git a/sites/eu/docs/pre-market/conformity-assessment/conformity-assessment-overview.md b/sites/eu/docs/pre-market/conformity-assessment/conformity-assessment-overview.md
@@ -117,11 +117,11 @@ Conformity assessment timelines vary significantly by:
 
 - [Annex IX — QMS + tech doc assessment](./annex-ix-qms-tech-doc.md)
 - [Annex X — EU type examination](./annex-x-type-examination.md)
-- [Annex XI — Product verification](./annex-xi-product-verification)
+- Annex XI — Product verification
 - [Class I self-declaration](./class-i-self-declaration.md)
-- [Class A self-declaration (IVDR)](./class-a-self-declaration)
+- Class A self-declaration (IVDR)
 - [EU Declaration of Conformity](./eu-declaration-of-conformity.md)
-- [CE marking requirements](./ce-marking-requirements)
+- CE marking requirements
 - [Notified bodies](/notified-bodies/what-notified-bodies-do)
 
 ---
diff --git a/sites/eu/docs/pre-market/udi-system/udi-overview.md b/sites/eu/docs/pre-market/udi-system/udi-overview.md
@@ -104,7 +104,7 @@ Note: UDI implementation timelines have undergone legislative adjustments via Co
 - [UDI-DI and UDI-PI explained](./udi-di-and-pi.md)
 - [EUDAMED UDI registration](./eudamed-udi-registration.md)
 - [UDI labelling requirements](./udi-labelling-requirements.md)
-- [UDI issuing entities](./udi-issuing-entities)
+- UDI issuing entities
 
 ---
 
diff --git a/sites/sa/docs/authorized-representative/ar-overview.md b/sites/sa/docs/authorized-representative/ar-overview.md
@@ -52,7 +52,7 @@ Foreign manufacturers who wish to keep their technical documentation confidentia
 - MDS-REQ 9 — Authorized Representative obligations
 - [AR Obligations](./ar-obligations.md)
 - [Changing Your AR](./changing-ar.md)
-- [MDEL for AR](./mdel-for-ar)
+- MDEL for AR
 
 To appoint an AR, identify a Saudi-licensed entity willing to act as your regulatory liaison. The prospective AR must hold (or be prepared to obtain) a valid MDEL AR license. Execute a properly authenticated and legalized AR contract that clearly defines roles, responsibilities, and obligations. Submit the AR appointment via GHAD as part of your initial MDMA application or as a change notification if updating an existing registration. The SFDA will validate the AR's MDEL status and licensing credentials before accepting the appointment.
 
diff --git a/sites/uk/docs/pre-market/clinical-evidence/clinical-investigations.md b/sites/uk/docs/pre-market/clinical-evidence/clinical-investigations.md
@@ -120,7 +120,7 @@ Clinical investigation data from investigations conducted in the UK, the EU, or
 - [Clinical evaluation requirements](./clinical-evaluation.md)
 - [Using overseas clinical data](./overseas-clinical-data.md)
 - [Performance evaluation for IVDs](./performance-evaluation.md)
-- [Special access — devices for evaluation purposes only](../../special-access/devices-for-evaluation)
+- Special access — devices for evaluation purposes only
 
 ---
 
diff --git a/sites/uk/docs/pre-market/conformity-assessment/overview.md b/sites/uk/docs/pre-market/conformity-assessment/overview.md
@@ -206,7 +206,7 @@ Once certified, the manufacturer must:
 
 - [Class I self-declaration pathway](./class-i-self-declaration.md)
 - [Class IIa · IIb · III — UKAB routes](./ukab-routes.md)
-- [Full QMS assessment (Annex II)](./full-qms-assessment)
+- Full QMS assessment (Annex II)
 - [UK declaration of conformity](./uk-declaration-of-conformity.md)
 - [UKCA marking requirements](./ukca-marking.md)
 - [UK Approved Bodies](../../approved-bodies/what-are-approved-bodies.md)
diff --git a/sites/uk/docs/pre-market/essential-requirements/design-construction-requirements.md b/sites/uk/docs/pre-market/essential-requirements/design-construction-requirements.md
@@ -85,7 +85,7 @@ For devices placed on the market in a sterile condition, manufacturers must:
 
 ### Reprocessing
 
-For devices intended to be reprocessed (cleaned, disinfected, re-sterilised between uses), the manufacturer must validate the reprocessing procedure and provide validated instructions in the IFU. See [Reprocessed single-use devices](../special-device-types/reprocessed-single-use-devices) and the Class Im sub-category for reusable surgical instruments.
+For devices intended to be reprocessed (cleaned, disinfected, re-sterilised between uses), the manufacturer must validate the reprocessing procedure and provide validated instructions in the IFU. See Reprocessed single-use devices and the Class Im sub-category for reusable surgical instruments.
 
 ---
 
diff --git a/sites/uk/docs/pre-market/essential-requirements/general-requirements.md b/sites/uk/docs/pre-market/essential-requirements/general-requirements.md
@@ -190,7 +190,7 @@ Together, they define the minimum standard of safety and performance that justif
 - [Design and construction — ER 7–17](./design-construction-requirements.md)
 - [IVD Essential Requirements (Schedule 1A)](./ivd-essential-requirements.md)
 - [Technical documentation overview](../technical-documentation/overview.md)
-- [Clinical evidence — what is required](../clinical-evidence/what-is-required)
+- Clinical evidence — what is required
 
 ---
 
diff --git a/sites/uk/docs/pre-market/mhra-registration/who-must-register.md b/sites/uk/docs/pre-market/mhra-registration/who-must-register.md
@@ -113,7 +113,7 @@ MHRA takes registration compliance seriously and conducts market surveillance to
 ## Related pages
 
 - [Registration via the MHRA Submissions portal](./mhra-submissions-portal.md)
-- [UKRP registration obligations](./ukrp-registration)
+- UKRP registration obligations
 - [Device-level registration requirements](./device-registration.md)
 - [UDI — Unique Device Identification](./udi.md)
 - [Who needs to comply?](../../start-here/who-needs-to-comply.md)
diff --git a/sites/uk/docs/pre-market/technical-documentation/overview.md b/sites/uk/docs/pre-market/technical-documentation/overview.md
@@ -212,10 +212,10 @@ Manufacturers should also retain technical documentation for as long as the devi
 
 - [Essential Requirements — overview](../essential-requirements/overview.md)
 - [ER checklist & compliance matrix](../essential-requirements/checklist-compliance.md)
-- [Device description & specifications](./device-description-specifications)
+- Device description & specifications
 - [Risk management (ISO 14971)](./risk-management.md)
 - [Clinical / performance evaluation summary](./clinical-evaluation-summary.md)
-- [Post-market data in the technical file](./post-market-data)
+- Post-market data in the technical file
 
 ---
 
diff --git a/sites/uk/docs/pre-market/technical-documentation/risk-management.md b/sites/uk/docs/pre-market/technical-documentation/risk-management.md
@@ -180,7 +180,7 @@ Software risks are managed through the integration of IEC 62304 (software lifecy
 - [General requirements — ER 1–6](../essential-requirements/general-requirements.md)
 - [Technical documentation overview](./overview.md)
 - [Clinical / performance evaluation summary](./clinical-evaluation-summary.md)
-- [Post-market data in the technical file](./post-market-data)
+- Post-market data in the technical file
 
 ---
 
diff --git a/sites/uk/docs/start-here/lifecycle-of-a-medical-device.md b/sites/uk/docs/start-here/lifecycle-of-a-medical-device.md
@@ -165,7 +165,7 @@ Manufacturers must provide **clinical evidence** appropriate to their device's c
 
 Clinical evaluation is not a one-time activity — it must be updated as part of post-market clinical follow-up (PMCF) throughout the device's market life.
 
-See [Clinical evidence](../pre-market/clinical-evidence/what-is-required).
+See Clinical evidence.
 
 ---
 
@@ -296,7 +296,7 @@ An FSCA may involve:
 
 All FSCAs and Field Safety Notices (FSNs) must be reported to MHRA.
 
-See [Field Safety Corrective Actions](../../post-market/vigilance/field-safety-corrective-actions).
+See Field Safety Corrective Actions.
 
 ---
 
diff --git a/sites/uk/docs/start-here/regulatory-framework-overview.md b/sites/uk/docs/start-here/regulatory-framework-overview.md
@@ -113,7 +113,7 @@ Any manufacturer **not established in the United Kingdom** who places a device o
 - Is jointly responsible for ensuring the device meets UK MDR 2002 requirements
 - Must be identified on the device label or packaging
 
-The UKRP role is analogous to the EU Authorised Representative (EU REP) in the EU framework. See [UK Responsible Persons](./who-needs-to-comply/ukrp) for full obligations.
+The UKRP role is analogous to the EU Authorised Representative (EU REP) in the EU framework. See UK Responsible Persons for full obligations.
 
 ---
 
diff --git a/sites/uk/docs/start-here/who-needs-to-comply.md b/sites/uk/docs/start-here/who-needs-to-comply.md
@@ -183,7 +183,7 @@ Carefully assess which role(s) your organisation occupies — each role carries
 
 ## Related pages
 
-- [UK Responsible Persons (UKRP) — full obligations](./who-needs-to-comply/ukrp)
+- UK Responsible Persons (UKRP) — full obligations
 - [MHRA registration](../pre-market/mhra-registration/who-must-register.md)
 - [Labelling requirements](../post-market/labelling-advertising/labelling-requirements.md)
 - [Great Britain vs Northern Ireland](./great-britain-vs-northern-ireland.md)
